Bxq-350- Phase 1, Dose-Escalation, Open-Label, Safety And Pharmacokinetic, First In Human Study Of Bxq-350 Administered As A Single Agent By Intravenous Infusion In Adult Patients With Advanced Solid Tumors And Recurrent High-Grade Gliomas
Posted Date: May 15, 2019
- Investigator: John Morris
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to test the safety of BXQ-350, an investigational drug, at different doses to find out what effects, if any, it has on people with cancer. An investigational drug means the drug is being tested and is not approved for sale by the regulatory authorities.
Criteria:
To Be Eligible: Must Have Advanced Solid Tumor Cancer Or High Grade Glioma, Age 18 Or Older, Nonpregnant/Breastfeeding, No Other Malignancy Within 1 Year, No Severe Infections
Keywords:
Glioma, Advanced, Tumor, Cancer, Phase I
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com